Al AE. Phase Ib stud y of MEDI4736, a programmed cell death ligand -1 (PD -L1) antibody , in combination with tremelimumab, a cy totoxic T -lymphocy te- associated protein- 4 (CTLA -4) antibody , in patients (pts) with advanced NSCL C. J.